BECONASE

This brand name is authorized in France, Hong Kong, Ireland, Lithuania, Mexico, New Zealand, Tunisia, United Kingdom, United States

Active ingredients

The drug BECONASE contains one active pharmaceutical ingredient (API):

1 Beclometasone dipropionate UNII 4H7L9AI22I - BECLOMETHASONE DIPROPIONATE MONOHYDRATE

Beclometasone is a pro-drug with weak glucocorticoid receptor binding affinity. It is extensively hydrolysed via esterase enzymes to the active metabolite beclometasone-17-monopropionate (B-17-MP), which has potent topical anti-inflammatory activity. Read about Beclometasone

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
BECONASE Aqueous suspension for intranasal inhalation	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
R01AD01	Beclometasone	R Respiratory system → R01 Nasal preparations → R01A Decongestants and other nasal preparations for topical use → R01AD Corticosteroids
Discover more medicines within R01AD01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: FR	Base de données publique des médicaments	Identifier(s): 63295400
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 198725, 29405, 29454, 299795, 64981
Country: HK	Department of Health Drug Office	Identifier(s): 28384
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1011964
Country: MX	Comisión Federal para la Protección contra Riesgos Sanitarios	Identifier(s): 079M90
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 2138
Country: TN	Direction de la Pharmacie et du Médicament	Identifier(s): 2113081
Country: US	FDA, National Drug Code	Identifier(s): 0173-0388